Volume 151, Issue 1, Pages (October 2018)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Survey on computer aided decision support for diagnosis of celiac disease Sebastian Hegenbart, Andreas Uhl, Andreas Vécsei Computers in Biology and Medicine.

Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: Results of the phase.

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Volume 19, Issue 3, Pages (March 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Pain in cancer survivors; filling in the gaps

Volume 149, Issue 2, Pages (May 2018)

Volume 145, Issue 2, Pages (May 2017)

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 144, Issue 2, Pages (February 2017)

Volume 147, Issue 1, Pages 3-10 (October 2017)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 26, Issue 2, Pages (February 2018)

Volume 136, Issue 2, Pages (February 2015)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Volume 150, Issue 1, Pages (July 2018)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Cone-Beam CT-based position verification for oesophageal cancer: Evaluation of registration methods and anatomical changes during radiotherapy A. van.

Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx:

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 17, Issue 8, Pages (August 2016)

Volume 4, Issue 5, Pages 2-3 (October 2006)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 3, Pages (September 2013)

Volume 130, Issue 1, Pages (July 2013)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 3, Pages (December 2017)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Clinical and Translational Radiation Oncology

Volume 20, Issue 9, Pages (September 2019)

Mark A. Socinski, MD Journal of Thoracic Oncology

Volume 154, Issue 2, Pages (August 2019)

Volume 154, Issue 1, Pages (July 2019)

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Volume 151, Issue 1, Pages 69-75 (October 2018) Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial B.G. Wortman, T. Bosse, R.A. Nout, L.C.H.W. Lutgens, E.M. van der Steen-Banasik, H. Westerveld, H. van den Berg, A. Slot, K.A.J. De Winter, K.W. Verhoeven-Adema, V.T.H.B.M. Smit, C.L. Creutzberg Gynecologic Oncology Volume 151, Issue 1, Pages 69-75 (October 2018) DOI: 10.1016/j.ygyno.2018.07.020 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 A – Study design of the PORTEC-4a trial. B – Decision tree of the molecular-integrated risk profile. Gynecologic Oncology 2018 151, 69-75DOI: (10.1016/j.ygyno.2018.07.020) Copyright © 2018 The Authors Terms and Conditions

Fig. 1 A – Study design of the PORTEC-4a trial. B – Decision tree of the molecular-integrated risk profile. Gynecologic Oncology 2018 151, 69-75DOI: (10.1016/j.ygyno.2018.07.020) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Cumulative accrual of the PORTEC-4a trial. Gynecologic Oncology 2018 151, 69-75DOI: (10.1016/j.ygyno.2018.07.020) Copyright © 2018 The Authors Terms and Conditions